PEPTIDE GUIDE

What Is VIP / Vasoactive Intestinal Peptide?

Vasoactive intestinal peptide, usually shortened to VIP, is a 28-amino-acid signalling peptide made throughout the nervous, digestive, respiratory, cardiovascular, reproductive and immune systems.

Its name reflects how it was discovered, not the limits of its biology. VIP can relax smooth muscle and widen blood vessels, but it also influences intestinal secretion, airway function, pancreatic signalling, circadian timing and immune-cell activity. It acts mainly through two receptors called VPAC1 and VPAC2.

Synthetic human VIP is called aviptadil. Aviptadil has been studied by inhalation and intravenous infusion in pulmonary hypertension, respiratory failure, sarcoidosis and other conditions. It is also one active ingredient in the regulated UK medicine Invicorp, which combines aviptadil with phentolamine for erectile dysfunction. Approval of that exact combination and route does not approve VIP injections, nasal sprays or inhaled products for unrelated purposes.

Research statusEstablished human biology; product and indication-specific clinical evidence
Compound typeEndogenous 28-amino-acid neuropeptide
Human evidenceExtensive physiology; mixed condition-specific trials
ApprovalAviptadil-phentolamine combination authorised for defined UK use
Last reviewedOctober 2026
THE SHORT ANSWER

VIP is an endogenous 28-residue neuropeptide and hormone with widespread local effects. It activates VPAC1 and VPAC2 receptors, usually increasing cyclic AMP inside responsive cells. Its actions include vasodilation, smooth-muscle relaxation, intestinal and pancreatic secretion, neural communication and immune modulation. Synthetic VIP, called aviptadil, is part of an approved intracavernosal combination medicine with phentolamine for erectile dysfunction in the UK. Other proposed uses remain indication and formulation specific. A 20-person pulmonary-hypertension study found only modest, short-lived haemodynamic effects after one inhaled exposure, while a 461-person NIH-sponsored COVID-19 respiratory-failure comparison found no significant clinical benefit and was stopped for futility. Evidence for one regulated product cannot be transferred to unapproved VIP products or to broad “healing” claims.

What kind of molecule is VIP?

Human VIP is a linear peptide containing 28 amino-acid residues. Its sequence is:

`HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2`

The C-terminus is amidated, meaning the final carboxyl group has been converted to an amide. That feature is important for biological activity. VIP belongs to the secretin-family of peptide hormones, alongside secretin, glucagon, glucose-dependent insulinotropic polypeptide, GLP-1, GLP-2, growth-hormone-releasing hormone and the closely related pituitary adenylate cyclase-activating polypeptide, or PACAP.

The isolated sequence does not behave like a stable oral small molecule. Peptidases can break it down rapidly, and its distribution depends heavily on route, formulation and tissue exposure. Endogenous VIP normally acts close to where nerves or other cells release it. A pharmaceutical dose entering the bloodstream or a local tissue can produce a different pattern of receptor activation.

Is VIP a hormone or a neurotransmitter?

It is both, depending on context. Neurons release VIP as a neurotransmitter or neuromodulator in the central and peripheral nervous systems. Endocrine and immune cells can release it as a local signalling molecule. In the gut it participates in enteric nervous-system control; in the brain it helps synchronise circadian networks; in blood vessels and smooth muscle it changes tone.

Labels such as “hormone”, “neuropeptide” and “immunomodulator” describe roles rather than separate versions of the molecule. They do not mean a dose placed anywhere in the body will reproduce a specific natural signal. Physiological VIP release is timed, local and rapidly terminated.

How was VIP discovered?

Sami Said and Viktor Mutt isolated a potent vasodilating peptide from porcine intestine around 1970 and later established its 28-residue structure. The name “vasoactive intestinal peptide” captured two early observations: it came from intestinal tissue and caused marked vascular effects.

Researchers soon found VIP-containing nerves beyond the bowel, including the lungs, brain, heart, pancreas and genitourinary system. Synthetic VIP was reported in the 1970s, allowing investigators to compare the manufactured sequence with material isolated from tissue.

Cloning of the peptide precursor and its receptors later placed VIP within the secretin-family signalling system. The discovery of PACAP added a closely related ligand that shares receptors but is not interchangeable with VIP.

PeriodDevelopment
1970sVIP isolated from porcine intestine, sequenced and chemically synthesised
1980sVIP gene and precursor biology characterised; distribution mapped across neural and peripheral tissues
1990sVPAC1 and VPAC2 receptor pharmacology defined; aviptadil combinations developed for erectile dysfunction
2000sInhaled aviptadil explored in pulmonary hypertension and inflammatory lung disease
2020 to 2023Aviptadil entered controlled COVID-19 respiratory-failure trials; the largest NIH-sponsored comparison was stopped for futility
Current positionOne regulated aviptadil-phentolamine combination has a defined erectile-dysfunction use in the UK; wider VIP uses remain investigational or unapproved

How is VIP made in the body?

The human VIP gene encodes a larger precursor protein rather than releasing the mature 28-residue peptide directly from a ribosome. Cells translate prepro-VIP, direct it into the secretory pathway and process it through enzyme cleavage and terminal modification.

The precursor also gives rise to peptide histidine methionine, often called PHM-27 in humans. Packaging into secretory vesicles allows nerve stimulation or other cellular signals to release VIP in a controlled manner.

This precursor biology matters when interpreting measurements. Gene expression, precursor protein, tissue staining and circulating mature VIP are not equivalent readouts. A change in one does not automatically prove more biologically active VIP reached a particular receptor.

What receptors does VIP activate?

VIP acts with high affinity at VPAC1 and VPAC2, two class B G-protein-coupled receptors. PACAP also activates both receptors and has especially high affinity for a third receptor called PAC1. VIP has far weaker activity at PAC1 than PACAP.

VPAC1 and VPAC2 often couple to stimulatory G proteins, activating adenylyl cyclase and increasing cyclic adenosine monophosphate, or cyclic AMP. Cyclic AMP is an intracellular messenger that can alter ion channels, secretion, smooth-muscle tone, gene expression and cell metabolism.

The distribution of receptors changes the response:

  • VPAC1 is prominent in many immune, epithelial, liver and gastrointestinal settings.
  • VPAC2 occurs in smooth muscle, parts of the nervous system, immune cells and circadian circuits.
  • Receptor density can change during inflammation, development and disease.

The pathway is not simply “anti-inflammatory”. VIP can suppress some inflammatory signals while supporting secretion, vascular leakage or other context-dependent processes. Dose, receptor balance and tissue state matter.

How does VIP differ from PACAP?

VIP and PACAP share substantial sequence similarity and both activate VPAC1 and VPAC2. PACAP exists mainly as PACAP-38 and PACAP-27 and strongly activates PAC1 as well.

That extra receptor preference can produce different neural and endocrine effects. A PACAP study cannot be treated as a VIP trial, and a VPAC-selective response cannot automatically be attributed to PAC1.

Commercial descriptions sometimes group the molecules together as if they were replacement versions of one pathway. In research, ligand identity, receptor selectivity, concentration and assay system must be specified.

What does VIP do in the digestive system?

VIP is widely distributed in enteric nerves. It relaxes gastrointestinal smooth muscle, including sphincter regions, and promotes secretion of water and electrolytes into the intestinal lumen. It can stimulate bicarbonate-rich pancreatic and biliary secretions while reducing gastric-acid output in some settings.

These actions help coordinate movement and digestion. Excessive VIP signalling also demonstrates the downside: rare VIP-secreting neuroendocrine tumours can cause profound watery diarrhoea, low potassium and reduced gastric acidity. The syndrome is often called WDHA, from watery diarrhoea, hypokalaemia and achlorhydria.

A VIPoma is therefore not evidence that extra VIP improves gut health. It is natural evidence that sustained systemic exposure can become dangerous. Diagnosis relies on the clinical picture, biochemical assessment and localisation of the tumour, not a single nonspecific symptom.

What does VIP do in the lungs?

VIP-containing nerves occur around airways and pulmonary vessels. Laboratory and physiological studies describe bronchodilation, pulmonary vasodilation, effects on mucus secretion and interactions with inflammatory and epithelial cells.

These features made synthetic VIP attractive for asthma, chronic inflammatory lung disease, sarcoidosis, pulmonary arterial hypertension and acute respiratory distress. The biological rationale is broader than the clinical proof.

An inhaled product may concentrate exposure in airways and pulmonary vessels while limiting systemic hypotension. Intravenous infusion creates a different exposure pattern and can cause vasodilation throughout the body. Results from one route should not be applied to another.

What does VIP do in the cardiovascular system?

VIP is a potent vasodilator in many vascular beds. Receptor activation can relax vascular smooth muscle and lower resistance. It can also affect heart rate, contractility and blood flow indirectly through autonomic and reflex responses.

Vasodilation is neither universally beneficial nor harmless. Lowering pressure in a constricted pulmonary circulation could reduce right-heart workload, while excessive systemic dilation could cause flushing, dizziness, low blood pressure or compensatory tachycardia.

The natural peptide's short exposure can limit and localise these effects. Stable analogues or continuous infusion may change both benefit and risk.

What role does VIP play in the brain and circadian timing?

VIP is expressed by a subset of neurons in the suprachiasmatic nucleus, the brain's principal circadian clock. Those neurons help synchronise cellular oscillators so daily rhythms remain coherent.

Animal models with disrupted VIP or VPAC2 signalling show abnormal coordination of circadian rhythms. This establishes a biological role but does not show that administering VIP improves sleep in people. Circadian networks depend on location and timing, and a peripheral product may not reproduce release within the suprachiasmatic nucleus or cross the blood-brain barrier predictably.

Claims about cognition, anxiety or sleep therefore remain far ahead of controlled therapeutic evidence for ordinary VIP administration.

How does VIP affect the immune system?

Immune cells can produce VIP and express VPAC receptors. Laboratory studies report effects on cytokine production, antigen-presenting cells, T-cell differentiation and innate immune responses. Many experiments find suppression of selected pro-inflammatory pathways and promotion of regulatory signals.

The phrase “immune balancing” is too vague to serve as a clinical claim. Suppressing a cytokine in cultured cells does not establish treatment of autoimmune disease, infection or chronic inflammation. Immune effects may differ with concentration, timing and the dominant receptor on each cell type.

VIP's rapid degradation and broad distribution also complicate drug development. A product intended to reach inflamed tissue must retain activity long enough to arrive without producing unwanted vascular or gastrointestinal effects elsewhere.

What is aviptadil?

Aviptadil is the pharmaceutical name for synthetic human VIP. The active sequence is intended to match the endogenous 28-residue peptide.

The name alone does not define a complete medicine. Aviptadil has been investigated as an intravenous solution, inhaled formulation and local intracavernosal component. Each has different excipients, concentration, pharmacokinetics and clinical evidence.

This is why “VIP is approved” is too broad. A regulator approves a specific product, route and indication, not every preparation containing the same nominal sequence.

What is the approved aviptadil product in the UK?

Invicorp combines aviptadil with phentolamine mesilate in a solution for intracavernosal injection. It is authorised for symptomatic treatment of erectile dysfunction in adult men. NHS Scotland accepted it for restricted use after failure of oral phosphodiesterase-5 inhibitors and other non-injectable options.

VIP helps relax penile smooth muscle and promote blood flow, while phentolamine blocks alpha-adrenergic constriction. Evidence and safety apply to the combination used locally under its product instructions.

The approval does not show that aviptadil alone treats erectile dysfunction, that systemic VIP is generally safe or that a research vial is equivalent to Invicorp. Combination evidence cannot isolate the precise contribution of each active ingredient without appropriate comparison groups.

What has aviptadil shown in pulmonary hypertension?

Pulmonary hypertension raises pressure in the vessels carrying blood through the lungs, increasing right-heart workload. VIP's pulmonary vasodilator action created a plausible therapeutic hypothesis.

In a 2008 study, 20 people with different forms of pulmonary hypertension inhaled a single aviptadil exposure during right-heart catheterisation. The study reported a small, temporary reduction in pulmonary vascular resistance, improved stroke volume and higher mixed venous oxygen saturation. Six participants had a reduction in pulmonary vascular resistance exceeding 20%.

The effect was described as modest and short-lived. There was no control group assessing longer-term symptoms, walking ability, hospitalisation or survival. The mixed population included pulmonary arterial hypertension, lung-disease-associated pulmonary hypertension and chronic thromboembolic disease, which have different biology and treatments.

The study shows acute haemodynamic activity. It does not establish aviptadil as a chronic pulmonary-hypertension medicine.

Why was aviptadil studied in COVID-19 respiratory failure?

Severe COVID-19 can injure the alveolar-capillary unit, provoke inflammation and impair oxygen exchange. VIP biology in pulmonary vessels, epithelial cells and immune signalling generated interest in aviptadil as a possible lung-protective treatment.

An industry-sponsored randomised Phase IIb/III study reported analyses suggesting improved recovery or survival in selected comparisons. Interpretation was complicated by endpoints, care setting and analysis choices. The larger independent test is especially important.

TESICO was an NIH-sponsored randomised, placebo-controlled trial conducted at 28 US sites. It compared intravenous aviptadil with matched placebo in adults with COVID-19-associated acute hypoxaemic respiratory failure. Of 471 randomised participants, 461 received at least part of an aviptadil or placebo infusion and entered the modified intention-to-treat analysis.

The independent monitoring board recommended stopping the aviptadil comparison for futility. At day 90, the odds ratio for a better category on the primary six-level outcome was 1.11, with a 95% confidence interval from 0.80 to 1.55 and p=0.54. Mortality was 38% with aviptadil and 36% with placebo.

The result did not demonstrate significant clinical benefit. It is a useful example of why receptor biology and smaller encouraging analyses must yield to a sufficiently rigorous controlled trial.

Has VIP been established for asthma, COPD or sarcoidosis?

Inhaled aviptadil has entered small or early studies in inflammatory respiratory conditions, including sarcoidosis. These programmes help assess local tolerability, biomarkers and signals, but they have not produced a broadly approved VIP respiratory medicine.

Airway disease is not one condition. Asthma involves variable bronchoconstriction and inflammation; COPD includes persistent airflow limitation and tissue damage; sarcoidosis forms granulomas; pulmonary arterial hypertension is primarily a vascular disorder. A shared biological pathway does not make evidence interchangeable.

An authority page should therefore resist turning several small programmes into the claim that VIP “repairs lungs”. The largest severe respiratory-failure trial did not improve its primary clinical outcome.

What is known about VIP and cancer?

Many tumours express VPAC receptors, and VIP-family signalling can affect proliferation, blood flow, immune interactions or secretion in laboratory systems. Researchers have explored receptor imaging, targeted delivery and receptor antagonists.

The direction is not uniformly protective. Depending on tumour type and experimental context, VIP signalling may influence growth or immune escape as well as provide a targeting marker. This ambiguity makes unsupervised systemic exposure especially difficult to justify.

Receptor expression in a tumour can be useful diagnostically without showing that VIP itself treats the cancer. There is no general clinical evidence that VIP is an anticancer peptide.

How is synthetic VIP manufactured?

A 28-residue amidated peptide can be produced by solid-phase peptide synthesis. Protected amino acids are coupled in the required sequence on a resin, the chain is cleaved, the C-terminal amide is generated through the synthesis design, and the crude material is purified.

Manufacturing challenges include incomplete couplings, deletion sequences, oxidation, deamidation, aggregation and adsorption to surfaces. A long peptide can adopt different conformations or lose material against containers and tubing, so formulation is not an afterthought.

Identity testing can combine intact-mass spectrometry, peptide mapping or sequencing and chromatographic methods. Content, related impurities, counterions, water and biological potency require separate assessment.

For inhaled or injectable medicine, particle characteristics or aerosol delivery, sterility, bacterial endotoxin, visible and subvisible particles, container closure and stability must also be validated. A nominal “99% purity” number does not establish all of these properties.

Why is stability a major development problem?

Endogenous VIP is designed for short-range signalling and is rapidly degraded in biological fluids. Enzymes can cleave the chain, while oxidation or deamidation can alter activity during storage.

Rapid clearance may limit systemic efficacy and require infusion or specialised delivery. Attempts to improve persistence include lipidation, cyclisation, amino-acid substitution, encapsulation and carrier systems. Each modification creates a new molecule or formulation whose receptor bias, distribution and safety need fresh testing.

This also means evidence for native aviptadil cannot be assumed for a “long-acting VIP” analogue. Greater half-life changes exposure throughout the body and could magnify hypotension, diarrhoea or immune effects.

What side effects are biologically plausible?

Potential effects follow from VIP pharmacology and route. Systemic vasodilation may cause flushing, headache, dizziness, low blood pressure or faster heart rate. Gastrointestinal secretion and smooth-muscle effects may produce abdominal symptoms or diarrhoea.

Local intracavernosal treatment has route-specific risks such as pain, bruising, bleeding, fibrosis and prolonged erection. Inhaled products raise separate questions about cough, airway response, delivered particle size and pulmonary exposure.

Immune reactions are possible with peptides and with impurities or aggregates. Short trials cannot reliably identify rare hypersensitivity or consequences of repeated long-term exposure.

Is VIP approved?

The accurate answer is product specific.

  • Endogenous VIP is a natural human signalling molecule, not a medicine approval.
  • Aviptadil plus phentolamine is authorised in the UK as Invicorp for a defined erectile-dysfunction indication and route.
  • Intravenous aviptadil is not an FDA-approved treatment for COVID-19 respiratory failure.
  • VIP products are not broadly approved for pulmonary hypertension, asthma, COPD, inflammatory disease, sleep, cognition or general recovery.

A natural sequence can be both a legitimate pharmaceutical ingredient in one product and an unapproved research substance in another.

How strong is the evidence overall?

QuestionBest available evidenceDefensible conclusion
Is VIP an important human signalling peptide?Decades of biochemical, receptor and physiological researchYes
Does synthetic VIP have human pharmacological effects?Local medicine use and clinical haemodynamic studiesYes, but effects depend strongly on route and formulation
Is aviptadil an established erectile-dysfunction medicine?Regulated aviptadil-phentolamine combination evidenceThe combination has a defined authorised use; this does not validate aviptadil alone
Does inhaled aviptadil treat pulmonary hypertension?Small single-dose study with modest, transient effectsChronic clinical benefit is not established
Does intravenous aviptadil improve severe COVID-19 outcomes?Large randomised placebo-controlled TESICO trialNo significant benefit was demonstrated
Does VIP treat autoimmune or inflammatory disease generally?Extensive laboratory biology and small condition-specific studiesNo general therapeutic conclusion
Are unregulated VIP products equivalent to regulated aviptadil?No comparative quality or clinical evidenceNo

VIP has one of the richest biological literatures in the peptide catalogue. Its therapeutic record is narrower. Wide distribution creates many plausible hypotheses, but it also makes selective drug delivery difficult.

What claims are not established?

VIP has not been established as a general treatment for “leaky gut”, chronic fatigue, long COVID, brain fog, ageing, immune dysregulation or exercise recovery. It is not a proven nootropic or sleep peptide.

Cell, animal or biomarker findings do not supply a human dose or validate nasal, inhaled or injectable research products. Claims should identify the molecule, formulation, route, condition and clinical endpoint rather than treating all VIP exposure as one intervention.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

What does VIP stand for?

VIP stands for vasoactive intestinal peptide, also called vasoactive intestinal polypeptide.

How many amino acids does VIP contain?

Mature human VIP contains 28 amino-acid residues and has an amidated C-terminus.

Is VIP made naturally in the body?

Yes. Neurons and other cells process it from a larger precursor and release it in the brain, gut, lungs, cardiovascular system and other tissues.

Is aviptadil the same as VIP?

Aviptadil is the pharmaceutical name for synthetic human VIP. A complete drug product also depends on formulation, route, manufacturing and indication.

Which receptors does VIP activate?

It activates VPAC1 and VPAC2 with high affinity. It is much less potent at the PAC1 receptor than PACAP.

Is VIP the same as PACAP?

No. They are related peptides that share VPAC receptors, but PACAP also strongly activates PAC1 and has its own evidence base.

Is VIP FDA approved?

There is no broad FDA approval for aviptadil as a respiratory, inflammatory or wellness treatment. Approval questions must refer to a specific product and jurisdiction.

Is VIP used in an approved UK medicine?

Yes. Aviptadil is combined with phentolamine in Invicorp for a defined erectile-dysfunction indication. This does not approve other VIP products or routes.

Does VIP lower blood pressure?

VIP can dilate blood vessels and lower vascular resistance. The size and safety of the effect depend on route, exposure and the person's condition.

Does VIP treat pulmonary hypertension?

A small study showed modest, short-lived haemodynamic effects after one inhaled exposure. Long-term clinical benefit has not been established.

Did aviptadil work for severe COVID-19?

The 461-participant TESICO comparison found no significant improvement in the primary day-90 clinical outcome and was stopped for futility.

Is VIP anti-inflammatory?

It can suppress selected inflammatory pathways in laboratory and animal systems. That does not establish it as a general anti-inflammatory treatment in people.

Does VIP improve sleep or circadian rhythm?

Endogenous VIP is important in the brain's circadian network, but ordinary administration has not been established as a sleep treatment.

Can VIP cause diarrhoea?

Yes. VIP promotes intestinal fluid and electrolyte secretion. Extreme endogenous excess from a VIPoma can cause severe watery diarrhoea and low potassium.

Why can a natural peptide still be risky?

Natural VIP is released locally and briefly. Pharmaceutical exposure can reach different tissues, concentrations and durations, and product impurities introduce additional risks.

Are nasal VIP products clinically validated?

No broadly approved nasal VIP product has established efficacy and safety for the wide range of claims made online.

What would stronger future evidence look like?

Future programmes need a defined molecule and formulation, adequate pharmacokinetics, receptor-informed dose selection and condition-specific outcomes. Respiratory trials should measure more than short-term biomarkers, and immune studies need clinically meaningful endpoints rather than broad cytokine panels.

Stable analogues may solve rapid degradation but create new pharmacology. They require direct comparison with native VIP and careful assessment of blood pressure, gastrointestinal effects, immunogenicity and off-target tissue exposure.

Negative findings are also informative. TESICO showed that compelling lung biology did not translate into improved severe-COVID outcomes. A trustworthy evidence base keeps that result visible when proposing the next indication.

The bottom line

VIP is a genuine, widely distributed human signalling peptide with important roles in neural communication, vascular tone, smooth muscle, secretion, circadian organisation and immune biology.

Synthetic VIP has also become real medicine in a narrow setting: aviptadil is one component of a regulated intracavernosal combination with phentolamine for erectile dysfunction. That fact should be described precisely rather than expanded into a general endorsement of VIP therapy.

Beyond that product, the evidence is mixed and route specific. Acute pulmonary effects have been measured, but chronic benefit in pulmonary hypertension is unproven, and a large independent respiratory-failure trial found no significant clinical improvement. VIP's biological breadth creates research value, not automatic therapeutic authority.

Research notice

This guide is educational. It does not provide dosing, administration, preparation, cycling, purchasing or self-treatment guidance.

Research reviewed through October 2026.